TheraRadar
← Back
Data updated: Mar 29, 2026

ALVOGEN

MetabolicDermatologyOncology
Generics

ALVOGEN is a generic drug manufacturer focused on Metabolic, Dermatology, Oncology. Key products include BONSITY.

1971
Since
44
Drugs
-
Trials
624
Approved (2yr)

Key Drugs

BONSITY
teriparatide
PTH receptor 1 indications · 2019
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE
buprenorphine hydrochloride
Kappa-opioid receptor 1 indications · 2013

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

PREGABALIN 2026-02-24
PREGABALIN 2026-02-23
Labeling
PREGABALIN 2026-02-23
Labeling
PREGABALIN 2026-02-23
Labeling
SODIUM PHENYLBUTYRATE 2026-02-17
TRAZODONE HYDROCHLORIDE 2026-02-09
Labeling
TRAZODONE HYDROCHLORIDE 2026-02-09
Labeling
PREGABALIN 2026-02-03
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Metabolic 25%
2 drugs Phase 1: 1
Dermatology 24%
2 drugs
Oncology 24%
2 drugs
Cardiovascular 16%
0 drugs Phase 3: 2
Respiratory 12%
1 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Bayer big-pharma
Oncology, Cardiovascular, Dermatology, Metabolic
AstraZeneca big-pharma
Oncology, Respiratory, Cardiovascular, Metabolic
Novartis big-pharma
Oncology, Cardiovascular, Respiratory
Boehringer Ingelheim big-pharma
Metabolic, Oncology, Respiratory, Cardiovascular
BRACCO specialty
Cardiovascular, Oncology, Metabolic, Respiratory